Comparative study on application of 177Lu-labeled rituximab, tetulomab, cetuximab and huA33 monoclonal antibodies to targeted radionuclide therapy › Research Explorer

Comparative study on application of ¹⁷⁷Lu-labeled rituximab, tetulomab, cetuximab and huA33 monoclonal antibodies to targeted radionuclide therapy

Research output: Contribution to journal › Article › peer-review

DOI

https://doi.org/10.1088/2057-1976/abd307
Final published version

Hesham M.H. Zakaly
Mostafa Y.A. Mostafa
Sergey Dzholumbetov
Shams A.M. Issa
H. O. Tekin
R. Uslu Erdemir
M. Zhukovsky

Original language	English
Article number	015015
Number of pages	11
Journal	Biomedical Physics and Engineering Express
Volume	7
Issue number	1
DOIs	https://doi.org/10.1088/2057-1976/abd307
Publication status	Published - Nov 2020

Research areas

BIODISTRIBUTION, NEUROENDOCRINE TUMORS, cetuximab, huA33, lutetium-177, monoclonal antibody, rituximab, targeted radionuclide therapy, tetulomab

ASJC Scopus subject areas

Nursing(all)

WoS ResearchAreas Categories

Radiology, Nuclear Medicine & Medical Imaging

ID: 20406920